HIV sero-status disclosure among people living with HIV (PLWH) is an important component of preventing HIV transmission to sexual partners. Due to various social, structural, and behavioral challenges, however, many HIV-infected opioiddependent patients do not disclose their HIV status to all sexual partners. In this analysis, we therefore examined non-disclosure practices and correlates of non-disclosure among high-risk HIV-infected opioid-dependent individuals. HIV-infected opioid-dependent individuals who reported HIV-risk behaviors were enrolled (N = 133) and assessed for HIV disclosure, risk behaviors, health status, antiretroviral therapy (ART) adherence, HIV stigma, social support and other characteristics. Multivariable logistic regression was used to identify significant correlates of non-disclosure. Overall, 23% reported not disclosing their HIV status to sexual partners, who also had high levels of HIV risk: sharing of injection equipment (70.5%) and inconsistent condom use (93.5%). Independent correlates of HIV non-disclosure included: being virally suppressed (aOR 0.19, p = 0.04), high HIV-related stigma (aOR 2.37, p = 0.03), and having multiple sex partners (aOR 5.87, p = 0.04). Furthermore, a significant interaction between HIV-related stigma and living with family/friends suggests that those living with family/friends were more likely to report not disclosing their HIV status when higher levels of perceived stigma was present. Our findings support the need for future interventions to better address the impact of perceived stigma and HIV disclosure as it relates to risk behaviors among opioid-dependents patients in substance abuse treatment settings.
Introduction
HIV sero-status disclosure to sexual partners is an important component of HIV prevention and treatment efforts because it facilitates informed decision-making before sexual contact [28, 41] . Improvements in the health and longevity of people living with HIV (PLWH), due to advances in medical science, may have important implications for both individual and public health outcomes [28, 42] . Disclosing HIV status to sexual partners has been generally linked to safer drugand sex-related practices (e.g., consistent condom use, lower frequency of drug use) [10, 30, 36] and reduction in HIV transmission [39, 41, 42] . In recent decades, increased attention to transmission within sero-discordant couples has highlighted the potential role of disclosure as a way to encourage prevention approaches including the use of pre-exposure prophylaxis (PrEP) and HIV treatment-as-prevention (TasP) [4, 8, 13] . Furthermore, disclosure can also help PLWH garner better social support, reduce psychological distress, and encourage them to access comprehensive medical care and support services [30, 47, 53] .
Despite its many potential benefits, disclosing one's HIVpositive status may have unintended negative consequences, like conflict with a partner, elevated stigma, depression, lack of social support, breach of confidentiality, rejection, and even violence, and therefore place significant burdens on PLWH [5, 6, 12, 21, 31, 41, 51, 52] . Due to individual and societal attitudes towards HIV and the possible negative consequences, disclosure is a sensitive issue and is often difficult to negotiate for many PLWH. For HIV-infected opioid-dependent individuals-a group of people who use drugs (PWUD)-who are often socially marginalized, it may involve an even more complex decision-making process [19, 30, 37] . Given the complexities surrounding HIV disclosure, they may be reluctant to disclose their HIV status and avoid disclosure altogether.
The decision to not disclose one's HIV status (i.e., nondisclosure) is multifaceted and influenced by structural, relational, and personal considerations. In the broader literature, several factors have been associated with non-disclosure [1, 2, 12, 16, 25, 35] . Despite significant research in this area, prior studies have not systematically investigated non-disclosure practices, nor have they explored theoretically informed correlates among HIV-infected opioid-dependent patients within drug treatment settings. An evidence-based understanding of the scope of non-disclosure can inform future interventions specifically tailored for this population. In this paper, we therefore sought to explore the factors associated with non-disclosure of HIV status to sexual partners among HIV-infected opioid-dependent patients.
Methods

Study Setting and Procedures
The data reported here are derived from the baseline assessment of the Holistic Health for HIV (3H+) project, a randomized controlled trial to improve HIV risk reduction and medication adherence among high-risk HIV-infected opioiddepenent patients. The study design and procedures of the parent study has been previously described [44] [45] [46] . Briefly, participants were recruited from community-based addiction treatment programs and HIV clinical care settings within the greater New Haven, Connecticut. Participants were recruited through clinic-based advertisements and flyers, word-ofmouth, and direct referral from counselors. Screening was conducted by trained research assistants either by phone or private room. Individuals who met inclusion criteria and expressed interest in participating provided informed written consent and were administered a baseline assessment. All participants were reimbursed for the time and effort needed to participate in the survey.
The study protocol was approved by the Institutional Review Boards at the University of Connecticut and Yale University, and received board approval from APT Foundation. Clinical trial registration was completed at http://www. Clini calTr ials.gov (NCT01741311).
Participants
Between September 2012 and January 2018, 133 HIVinfected, opioid-dependent individuals were recruited. Additional inclusion criteria included: (1) being 18 years or older; (2) reporting drug-or sex-related risk behavior (past 6 months); (3) being able to understand, speak, and read English; and (4) not actively suicidal, homicidal, or psychotic.
Measures
Participants were assessed using an audio computerassisted self-interview (ACASI). Measures included sociodemographic characteristics, health status, HIV-related stigma, drug-and sex-related risk behaviors, and serostatus non-disclosure. Key measures are described below.
The dependent variable was non-disclosure of HIV status, which was defined as having any sex without disclosure of HIV-positive status to the partners in the past 6 months. Sero-status non-disclosure to partners was measured as "yes"/"no" by asking, "In the past 6 months, did you have sex with anyone that you did not tell your HIV status sometime before you had sex?"
Health status variables including length of time since HIV diagnosis, whether the participant was currently taking antiretroviral therapy (ART), and baseline viral load (VL) and CD4 count were abstracted from their medical record. Adherence to ART in the past month was assessed using a empirically validated, self-report visual analog scale (VAS) approach [18] . Using standardized cut-off, adherence of 95% or greater was considered optimal adherence [38] . Viral suppression was defined as clinicrecorded HIV-1 RNA test value < 200 copies/mL and high CD4 count (≥ 500 cells/mL) [3, 11] .
Measures related to the information-motivation-behavioral skills (IMB) model constructs associated with HIV risk reduction [23] HIV-related stigma was measured using a validated 24-item HIV stigma scale [15] with items rated on 5-point Likert-type scales with higher scores indicating greater stigma. Items were averaged to create a composite score (α = 0.93).
The HIV risk assessment, adapted from NIDA's risk behavior assessment [14] was used to measure several aspects of HIV risk behaviors in the past 30 days, including a measurement of "any" high risk behavior (sexual or 1 3 drug-related) as well as measurements of event-level (i.e., partner-by-partner) behaviors.
Data Analyses
Covariates included in the analysis were based on prior research as well as findings from other studies conducted within drug treatment settings. We computed descriptive statistics, including frequencies and percentages for categorical variables, and means and standard deviations for continuous variables. We conducted bivariate analyses for significant associations with the dependent variable (i.e., non-disclosure of HIV status). Additionally, we included the interaction term (variables from the main effects model), one at a time, in the model containing all the main effects to determine the interactive effect on non-disclosure. We then conducted multivariable logistic regression analyses on bivariate associations found to be significant at p < 0.10.
Stepwise forward entry and backward elimination methods both showed the same results in examining the independent correlates (p < 0.05) expressed as adjusted odds ratios (aOR) and their 95% confidence intervals. Model fit was assessed using a Hosmer and Lemeshow test [22] . Collinearity between variables was assessed using the variance inflation factor (VIF). Estimates were evaluated for statistical significance based on p < 0.05. All analyses were conducted using SPSS version 23 [24] .
Results
The baseline characteristics are described in Table 1 . The mean age of participants was 49.3 (± 8.3), and 41.4% were living with family/friends. The mean duration of HIV diagnosis was 14.1 (± 9.6) years and were maintained on a stable methadone dose (Mean: 64.5 mg). Of 121 (91.0%) individuals who were taking ART, 57.9% had achieved optimal adherence and 80.4% had a high CD4 count. HIV-related stigma scores ranged from 1.0 to 4.4, with a mean score of 2.0 (± 0.7). Self-reported HIV risk behaviors were highly prevalent among study samples. Almost half of the participants (46.6%) reported to have injected illicit drugs in the past 30 days. Of those, 58.1% reported having shared injection equipment. Similarly, 21.1% of the participants reported having sex with more than one sexual partner and only 14.3% reported to have always used condoms with their sexual partners in the past 30 days (Fig. 1) .
Nearly a third (23%) of the participants reported not disclosing their HIV status with a sexual partner, whereas, 39.8% of them reported to know their sexual partner's HIV status. Table 1 describes the bivariate comparisons of those reporting non-disclosure. Of note, there was significant difference based on participants' knowledge of sexual partner's HIV status (p = 0.002) and whether they had multiple sex partner (p < 0.001), which is portrayed in Fig. 1 . Other factors in bivariate analysis associated with non-disclosure were being older (p = 0.005) and heterosexual (p = 0.013). Table 2 shows the independent correlates associated with HIV-positive status non-disclosure. Participants who were virally suppressed were less likely to withhold disclosing their HIV status to sexual partners (aOR 0.189, p = 0.041). Whereas, participants with a higher degree of perceived HIV-related stigma (aOR 2.366, p = 0.032) and having multiple sex partners (aOR 5.868, p = 0.040) were significantly more likely to not disclose their HIV status. Furthermore, we also found a significant interaction between stigma and living with family/friends on non-disclosure (aOR 7.792, p = 0.020).
Discussion
Several important findings were gleaned with regard to non-disclosure practices among high-risk HIV-infected opioid-dependent individuals, and these may have significant implications for future HIV prevention efforts in the clinical settings. A substantial proportion of participants in our study reported not disclosing their HIV status to any sexual partner. This finding underscored the complexities and challenges surrounding HIV sero-status disclosure among high-risk opioid-dependent patients in drug treatment settings. The higher rate of non-disclosure in our sample may be partially explained by a longstanding experience with drug use (e.g., mean duration: 24.7 years). One potential explanation is that those with longstanding drug use may have been subjected to discrimination before HIV treatment could potentially render PLWH non-infectious to others and now continue to perceive that the risk of sero-status disclosure outweighs the potential benefits [30, 49] . Furthermore, the dual veils of stigma derived from both addiction and HIV creates synergistic jeopardy that reduces their willingness to disclose their status. Findings from this study support previous studies demonstrating that the HIV sero-status disclosure process is difficult and complex, especially for high-risk HIV-infected opioid-dependent individuals in drug treatment.
We found that self-reported HIV risk behaviors (both drug-and sex-related) were highly prevalent among this sample, which is consistent with findings from prior studies with similar risks [9, 27, 43, 45] . A significant proportion of participants reported sharing of injection equipment, having multiple sex partners, and inconsistent condom use during sexual intercourse. This is especially concerning given that they are continuing to engage in risky behaviors with most of them not disclosing their HIV status, and thus may be transmitting HIV to sero-discordant partner. These findings highlight the importance of HIV status disclosure and the need for additional evidence-based HIV prevention strategies. As such, the delivery of integrated PrEP and ART may be the most pragmatic HIV prevention strategy among HIVserodiscordant couples [4, 8, 13] . In this study, the odds of non-disclosure of HIV serostatus was lower among individuals who were virally suppressed. Although being virally suppressed has been shown to prevent sexual transmission of HIV [7] , it is encouraging that these individuals report a willingness to disclose their sero-status. Feelings of responsibility and the desire to protect one's sexual partners from potential HIV infection may have enhanced motivation to disclose their HIV status, and thereby overriding concerns about negative consequences [37] . Furthermore, we found that greater HIV-related stigma was associated with non-disclosure of HIV status to sexual partners, which is consistent with the literature on stigma and disclosure [17, [33] [34] [35] 41] . It is possible that negative beliefs around one's HIV status and the associated damaging consequences may reduce the likelihood that HIV status Percentage is disclosed in a sexual context [35] . HIV-related stigma remains a considerable barrier to ending the pandemic, necessitating effective strategies that directly provide access to information, community support, and advocacy. One strategy that has been rapidly gathering momentum in the recent years is the Undetectable = Untransmittable (U = U) campaign [40, 48] . It synthesizes scientific data from the TasP literature [20, 50] and places PLWH as being responsible for HIV transmission by caring enough to optimally adhere to HIV medications, rendering themselves unable to transmit HIV irrespective of ongoing sexual risk. Such strategies remove the absolute need to disclose their HIV status and markedly reduces the consequences to PLWH through the disclosure process. The pro-social U = U campaign empowers PLWH so that by protecting themselves, they protect others even when HIV disclosure is not addressed. Additionally, participants who reported having multiple sex partners were more likely to not disclose their HIV status. With multiple sex partners, the complex dynamics of relationship [32] may increase fears of rejection, and thus, lead to non-disclosure. Our findings further demonstrated that there is a complex interplay between HIV-related sigma, family/friend support, and non-disclosure. As an extension of prior findings, our results showed an interactive effect of stigma and living with family or friends on individuals' non-disclosure practices. That is, those living with family/ friends were more likely to report not disclosing their HIV status when faced with a higher degree of perceived stigma. Social support is an important psychological factor that can promote HIV status disclosure [26, 29] , but situational variables such as HIV-related stigma may override the positive influence of social support in decisions about disclosure. This buffering incluence can help explain how disclosure practices among PLWH changes in the presence of social support and how stigma impacts long-term social support and PLWH's willingness and/or patterns of disclosure. From a prevention standpoint, this highlights the importance of precisely targeting the impact of perceived stigma and increasing social support, while developing interventions to improve disclosure practices among HIV-infected opioiddepenent patients.
The findings from this study are not without limitations. First, the sample was drawn from individuals enrolled in MMT, potentially limiting generalizability of findings to HIV-infected opioid-dependents individuals not enrolled in the methadone program. Second, we utilized a dichotomous measure of HIV sero-status non-disclosure status obtained from a single-item question. Furthermore, we did not assess non-disclsoure status at a partner specific level. We are therefore unable to fully capture the complexity and circumstances of non-disclosure to sexual partners. Third, much of the data in this study came from self-report and is thus subject to both social desirability and recall biases. Fourth, the data in this study were cross-sectional in nature, thus limiting our ability to infer causation from the associations found. Fifth, this study included relatively small sample size which may have limited our ability to detect differences with smaller effect size. Last, the current study was focused on non-disclosure to sexual partners, potentially limiting our ability to assess HIV transmission risk through sharing of injection equipment among injecting partners. Despite these limitations, the findings from this study significantly contribute to the literature to date, in which there is little research investigating non-disclosure patterns among this underserved population.
Conclusions
HIV sero-status disclosure to sexual partners is an important component of HIV prevention and treatment efforts [28, 41] . Findings from this study underscore the complexities surrounding HIV sero-status non-disclosure/disclosure among high-risk HIV-infected opioid-dependent patients, as highlighted by the relatively high rates of HIV non-disclosure. Our findings are unique given the relative dearth of research on HIV non-disclosure practices and associated factors among this risk group. In the contemporary era of TasP, interventions that reduce the complexity of disclosure by reducing risks to others, like U = U, are crucial for providing the foundation for allowing the disclosure process to evolve over time. Given high prevalence of HIV status non-disclosure (23%) in this high-risk population, future interventions should consider the specific needs of the population (e.g., harm reduction, overcoming stigma, improving social support) that better address the impact of perceived stigma and HIV disclosure as it relates to risk behaviors among opioiddependent enrolled in treatment.
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